Aims Treatment of iron deficiency (ID) in patients with heart failure (HF) with intravenous iron
substitution [ferric carboxymaltose (FCM)] has previously shown significant improvements in …

Aims The purpose of this study was to evaluate the cost‐effectiveness of iron repletion using
intravenous (iv) ferric carboxymaltose (FCM) in chronic heart failure (CHF) patients with iron …

Aims Iron deficiency (ID) is comorbid in up to 50% patients with heart failure (HF) and
exacerbates disease burden. Ferric carboxymaltose (FCM) reduced HF hospitalizations and …

Abstract Background and Aims Whereas a beneficial effect of intravenous ferric
carboxymaltose (FCM) on symptoms and exercise capacity among patients with iron …

Aims Iron deficiency is common in patients with heart failure (HF). In AFFIRM‐AHF, ferric
carboxymaltose (FCM) reduced the risk of hospitalisations for HF (HHF) and improved …

Aims This analysis aims to evaluate the budget impact of intravenous iron therapy with ferric
carboxymaltose for patients with systolic chronic heart failure and iron deficiency, from the …

Aims Therapy with iv iron in patients with chronic heart failure (CHF) and iron deficiency (ID)
improves symptoms, functional capacity, and quality of life. We sought to investigate whether …

Aim The aim of this study was to evaluate the benefits and safety of long-term iv iron therapy
in iron-deficient patients with heart failure (HF). Methods and results CONFIRM-HF was a …

Abstract Objectives. Guidelines of the European Society of Cardiology (ESC) recommend
that ferritin and transferrin saturation should be tested in chronic heart failure (HF) and state …

Aims Iron deficiency (ID) is a common co‐morbidity in patients with heart failure (HF) and
has been suggested to be associated with poor prognosis. Recently completed double …